These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 12171017)

  • 1. "Switch" studies for people with lipodystrophy.
    Proj Inf Perspect; 2000 Aug; (30):9. PubMed ID: 12171017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipodystrophy.
    Proj Inf Perspect; 1999 Apr; (27):14-5. PubMed ID: 11366731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switching drugs for lipodystophy.
    Fornataro K
    Body Posit; 1999 May; 12(5):13. PubMed ID: 11366306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Switch strategy: replacing the protease inhibitor. Quality of life improves].
    MMW Fortschr Med; 2000; 142(3 Suppl):37. PubMed ID: 11012292
    [No Abstract]   [Full Text] [Related]  

  • 5. On the trail of fugitive fat: the chase turns to NRTIs.
    Mascolini M
    J Int Assoc Physicians AIDS Care; 1999 Oct; 5(10):24-43. PubMed ID: 11366871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting body shape changes.
    TreatmentUpdate; 2002 Nov; 14(8):7. PubMed ID: 12501828
    [No Abstract]   [Full Text] [Related]  

  • 7. Lipodrama.
    Horn T
    Res Initiat Treat Action; 1999 Dec; 5(5):13-5. PubMed ID: 11366885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipodystrophy studies in women.
    Proj Inf Perspect; 1999 Apr; (27):16. PubMed ID: 11366732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Body changes and blood abnormalities: the lipodystrophy and fat redistribution conundrum.
    Martinez LJ
    Res Initiat Treat Action; 1999 Apr; 5(2):22-5. PubMed ID: 11366281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug reactions & lipodystrophy workshop.
    Coppedge B
    STEP Perspect; 1999; 99(3):17-8. PubMed ID: 11366865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Indinavir-associated lipodystrophy].
    Krautheim A
    Praxis (Bern 1994); 1999 Feb; 88(7):285-7. PubMed ID: 10097649
    [No Abstract]   [Full Text] [Related]  

  • 12. Metabolic complications of HIV-1 antiretroviral therapy: the lipodystrophy syndrome.
    Borderi M; Verucchi G; Tadolini M; Spinosa S; Fortunato L; Talò S; Chiodo F
    New Microbiol; 2001 Jul; 24(3):303-15. PubMed ID: 11497090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are changes in body shape due to drug side effects?
    TreatmentUpdate; 1999 Jun; 11(4):3-4. PubMed ID: 11366790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benefit of switching from a protease inhibitor (PI) to nevirapine in PI-experienced patients suffering acquired HIV-related lipodystrophy syndrome (AHL): interim analysis at 3 months of follow-up.
    Negredo E; Paredes R; Bonjoch A; Tuldrà A; Fumaz CR; Gel S; Garcés B; Johnston S; Arnó A; Balagué M; Jou A; Tural C; Sirera G; Romeu J; Cruz L; Francia E; Domingo P; Arrizabalaga J; Ruiz I; Arribas JR; Ruiz L; Clotet B
    Antivir Ther; 1999; 4 Suppl 3():23-8. PubMed ID: 16021868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Increased girth, thin arms. Unusual changes in HIV therapy].
    MMW Fortschr Med; 1999 Sep; 141(36):62-3. PubMed ID: 10904607
    [No Abstract]   [Full Text] [Related]  

  • 16. Lipodystrophy in HIV-infected pediatric patients receiving protease inhibitors.
    Temple ME; Koranyi KI; Nahata MC
    Ann Pharmacother; 2003 Sep; 37(9):1214-8. PubMed ID: 12921501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipodystrophy--nukes vs. protease inhibitors.
    TreatmentUpdate; 2001 Jul; 13(3):5-6. PubMed ID: 11569989
    [No Abstract]   [Full Text] [Related]  

  • 18. [Facial lipodystrophy in patients with HIV infections troublesome to treat].
    Walther RA
    Lakartidningen; 2002 Sep; 99(39):3826-9. PubMed ID: 12395531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of reducing stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patients.
    Milinkovic A; Martinez E; López S; de Lazzari E; Miró O; Vidal S; Blanco JL; Garrabou G; Laguno M; Arnaiz JA; Leon A; Larrousse M; Lonca M; Mallolas J; Gatell JM
    Antivir Ther; 2007; 12(3):407-15. PubMed ID: 17591031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fat loss prompts SA treatment switch.
    IAPAC Mon; 2006 Jul; 12(7):212. PubMed ID: 17096492
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.